Others
Posted 18/06/2012
First posted: 12 August 2011 Concerning biosimilars approved and marketed in The Netherlands, view the following related article: Biosimilars approved and marketed in The Netherlands The Netherlands is already a mature (well-established) market* in the use of generic medicines.
The market share of generic medicines by volume in 2008 was more than 56%, representing less than 15% in value [1]. However, generic presence could still be improved, and the following are some ideas that could help to increase the generic market share in The Netherlands: Recommendations * A mature generic market is one where generics have been on the market for more than 10 years and where the market share of generics exceeds 40% [2]. References 1. Bond van de Generieke Geneesmiddelenindustrie Nederland (Bogin), Information in English [page on the Internet]. The Hague, The Netherlands, Bogin [cited 2011 May 13]. Available from: www.bogin.nl/english 2. Simoens S, De Coster S. Sustaining Generic Medicines Markets in Europe. April 2006. [monograph on the Internet]. Brussels, Belgium, European Generic Medicines Association (EGA) [cited 2011 May 13]. Available from:www.egagenerics.com/doc/simoens-report_2006-04.pdf